{"entity":{"id":"bi-1808","kind":"drug","name":"BI-1808","aka":[],"tldr":"BI-1808 is an experimental monoclonal antibody from BioInvent International, in phase 2 trials for cutaneous T-cell lymphoma, T-cell lymphoma and ovarian cancer and other cancers.","summary":"BI-1808 is a monoclonal antibody from BioInvent International. A first-in-class anti-TNFR2 antibody that is part of BioInvent's programme targeting tumour-associated regulatory T cells; tested alone and with pembrolizumab. Its furthest stage is phase 2, for cutaneous T-cell lymphoma, T-cell lymphoma, ovarian cancer and melanoma. ClinicalTrials.gov registers it in one study linked below. Phase 1/2a NCT04752826 recruiting (registry, checked 3 Nov 2026); updated phase 2a CTCL data presented at EHA 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"BioInvent International: bioinvent.com","url":"https://www.bioinvent.com/en/clinical-programs/our-programs/bi-1808-t-cell-lymphoma"},{"label":"BioInvent International: bioinvent.com","url":"https://www.bioinvent.com/en/clinical-programs/our-programs/bi-1808-t-cell-lymphoma"},{"label":"ClinicalTrials.gov: trials of BI-1808","url":"https://clinicaltrials.gov/search?intr=BI-1808"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","melanoma","metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["bioinvent-international"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04752826"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"BI-1808","modality":"Monoclonal antibody","mechanism":"A first-in-class anti-TNFR2 antibody that is part of BioInvent's programme targeting tumour-associated regulatory T cells; tested alone and with pembrolizumab.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bi-1808/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"bioinvent-international","kind":"company","name":"BioInvent International","route":"/companies/bioinvent-international/"}],"trial":[{"id":"nct04752826","kind":"trial","name":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","route":"/trials/nct04752826/"}]}}